Indaptus Therapeutics FY EPS $(1.83) Beats $(1.95) Estimate; Cash Balance Of $13.4M Will Provide Runway Through Q3 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics reported a FY EPS of $(1.83), surpassing the $(1.95) estimate. Despite a 5.78% increase in losses from the previous year, its $13.4M cash balance is expected to sustain operations through Q3 of 2024.
March 13, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indaptus Therapeutics beats EPS estimates and reports a cash balance sufficient to last through Q3 2024, despite increased losses.
Beating EPS estimates generally has a positive impact on investor sentiment, potentially leading to a short-term increase in stock price. The assurance of operational sustainability through Q3 2024, despite a year-over-year increase in losses, adds to the positive outlook by reducing immediate financial risk concerns.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90